Form 4: GeneDx Holdings Corp. Insider Transactions
Statement of Changes in Beneficial Ownership
Katherine Stueland, CEO of GeneDx Holdings Corp., reported transactions involving Class A Common Stock and Restricted Stock Units.
Summary
- Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp., engaged in transactions on June 9, 2026.
- She acquired 6,546 shares of Class A Common Stock through the settlement of Restricted Stock Units (RSUs) with no cost.
- Concurrently, 3,639 shares of Class A Common Stock were disposed of for $53.77 per share to cover tax withholding obligations related to RSU vesting.
- Following these transactions, Stueland beneficially owns 96,123 shares of Class A Common Stock directly.
- Additionally, she holds RSUs representing contingent rights to up to 324,275 shares and options for up to 107,610 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions for tax purposes rather than significant strategic shifts or performance indicators.
Positives
- Acquisition of 6,546 shares of Class A Common Stock via RSU settlement indicates continued equity incentive for management.
- The CEO's direct beneficial ownership of 96,123 shares demonstrates a significant personal stake in the company.
Negatives
- Sale of 3,639 shares to cover tax withholding obligations, while standard, represents a reduction in immediate shareholding.
Future Outlook
The filing does not contain forward-looking statements or guidance. It reports on past transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive equity holdings and movements. These transactions are common for executives managing tax liabilities associated with equity compensation.
Stakeholder Impact
- Shareholders: Increased transparency into executive equity holdings and potential tax-related share sales.
Key Dates
| Date | Description |
|---|---|
| 03/09/2023 | First tranche of RSUs vested. |
| 06/09/2026 | Date of transactions reported in Form 4 (acquisition and disposition of stock). |
| 06/11/2026 | Date of signature on the Form 4 filing. |
Keywords
GeneDx Holdings Corp., Katherine Stueland, Form 4, Insider Transaction, Class A Common Stock, Restricted Stock Units, RSU, CEO, Director, Beneficial Ownership, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.